Testing for Recurrence
Early-stage colorectal cancer patients may benefit from a new test that predicts their risk of recurrence.
Read More
Bone Drug in Limbo
The FDA decides to wait on reviewing Prolia (denosumab) for reducing treatment-related bone loss in breast and prostate cancer patients, but a new study may shed light on the drug’s importance.